Robert Bessler Sells LifeStance Shares Worth $492K
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy LFST?
Source: Fool
- Transaction Overview: Director Robert Bessler sold 69,899 shares of LifeStance Health Group in multiple open-market transactions on April 23 and 24, valued at approximately $492,000, indicating his ongoing engagement with the company's stock.
- Holding Changes: This sale represented 2.47% of Bessler's total holdings, leaving him with 57,619 shares directly and over 2.7 million shares indirectly, demonstrating his substantial economic interest in the company.
- Company Performance: LifeStance reported $1.4 billion in revenue for 2025, a 14% year-over-year increase, and achieved a net income of $9.7 million, marking a significant turnaround from a net loss of $57.4 million in 2024, showcasing strong business performance and growth potential.
- Market Reaction: Despite Bessler's stock sale, LifeStance shares recently hit a 52-week high of $8.09, with projected revenue of $1.6 billion for 2026, reflecting strong market confidence in the company's future growth prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LFST?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LFST
Wall Street analysts forecast LFST stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 7.570
Low
8.00
Averages
9.07
High
10.00
Current: 7.570
Low
8.00
Averages
9.07
High
10.00
About LFST
LifeStance Health Group, Inc. is a reimagining mental health company. The Company is focused on providing virtual and in-person outpatient mental healthcare for children, adolescents and adults experiencing a variety of mental health conditions. Its patient-focused platform combines differentiated clinical capabilities with a personalized, digitally powered patient experience designed to transform patient access and treatment. Its clinicians offer patients a comprehensive, multidisciplinary suite of mental health services, spanning psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family and group therapy. It treats a range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders and post-traumatic stress disorder. It employs approximately 7,400 psychiatrists, advanced practice nurses, psychologists and therapists and operates across 33 states and more than 550 centers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Robert Bessler Sells LifeStance Shares Worth $492K
- Transaction Overview: Director Robert Bessler sold 69,899 shares of LifeStance Health Group in multiple open-market transactions on April 23 and 24, valued at approximately $492,000, indicating his ongoing engagement with the company's stock.
- Holding Changes: This sale represented 2.47% of Bessler's total holdings, leaving him with 57,619 shares directly and over 2.7 million shares indirectly, demonstrating his substantial economic interest in the company.
- Company Performance: LifeStance reported $1.4 billion in revenue for 2025, a 14% year-over-year increase, and achieved a net income of $9.7 million, marking a significant turnaround from a net loss of $57.4 million in 2024, showcasing strong business performance and growth potential.
- Market Reaction: Despite Bessler's stock sale, LifeStance shares recently hit a 52-week high of $8.09, with projected revenue of $1.6 billion for 2026, reflecting strong market confidence in the company's future growth prospects.
See More
Director Robert Bessler Sells Shares of LifeStance Health Group
- Share Sale Details: Director Robert Bessler sold 69,899 shares of LifeStance Health Group between April 23 and 24, 2026, for approximately $492,000, representing 2.47% of his total holdings, indicating his continued confidence in the company despite the sale.
- Ownership Structure: Post-transaction, Bessler retains about 57,619 shares directly and 2.7 million shares indirectly, demonstrating a strong commitment to LifeStance as a long-term investment even after partial divestment.
- Company Performance: LifeStance reported a 14% year-over-year revenue increase in 2025, reaching $1.4 billion, and successfully reversed a net loss from 2024 into a net income of $9.7 million, showcasing a robust business recovery.
- Market Outlook: Although LifeStance's forward price-to-sales ratio has risen to 2, reflecting its stock price increase, the company expects revenue to reach $1.6 billion in 2026, indicating ongoing growth potential, prompting investors to carefully assess its investment value.
See More
S&P Dow Jones Indices: LifeStance Health Group to Take the Place of Golden Entertainment in S&P SmallCap 600 Starting May 1 Before Market Opens
Company Announcement: S&P Dow Jones Indices has announced that Lifestance Health Group will replace Golden Entertainment in the S&P SmallCap 600 index.
Effective Date: This change will take effect prior to the opening of trading on May 1.
See More
Lifestance Health Group to be Added to S&P SmallCap 600, According to S&P Dow Jones Indices
- S&P Dow Jones Indices Update: The S&P Dow Jones Indices has announced that Lifestance Health Group will be joining the S&P SmallCap 600 index.
- Impact on Market: This inclusion is expected to enhance the visibility and credibility of Lifestance Health Group within the financial markets.
See More
Wall Street's Optimistic Price Targets for Stocks
- LifeStance Health Risks: LifeStance Health Group (LFST) has a revenue base of only $1.42 billion, lacking the economies of scale enjoyed by industry giants, and its free cash flow margin of 0.5% over the past five years constrains its ability to self-fund growth or return capital, with a current share price of $6.90 reflecting a forward P/E of 22.9.
- Meta's Growth Potential: Meta (META) has achieved a 29.9% annual growth in average revenue per user over the past two years, and its stock buybacks have led to a 51.3% increase in earnings per share, with a current share price of $672.76 and a forward EV/EBITDA of 12.2, indicating strong profitability and investment returns.
- Permian Resources' Strong Performance: Permian Resources (PR) has seen an impressive annual revenue growth of 43.3% over the last decade, boasting a best-in-class gross margin of 75.7% and a free cash flow margin of 27.2%, with a current stock price of $20.40 reflecting a forward P/E of 10.4, showcasing flexibility in capital deployment.
- Market Outlook Analysis: While analysts set optimistic price targets for these stocks, caution is advised as market sentiment can lead to overly optimistic forecasts, prompting investors to focus on the companies' fundamentals and potential risks.
See More
LifeStance Health Group to Release Q1 2026 Earnings
- Earnings Release Schedule: LifeStance Health Group is set to release its Q1 2026 earnings before the market opens on May 7, 2026, reflecting the company's ongoing commitment to transparency and investor communication.
- Conference Call Details: The company will host an earnings conference call at 8:30 a.m. Eastern Time on the same day, with investors able to dial in at 1-800-715-9871, demonstrating the importance placed on investor engagement.
- Webcast Availability: The earnings call will be accessible via a real-time audio webcast on the LifeStance Investor Relations website, with related materials posted prior to the call, enhancing the accessibility of information for stakeholders.
- Company Background: Founded in 2017, LifeStance has become one of the largest outpatient mental health care providers in the U.S., employing approximately 8,000 professionals across 33 states and over 550 centers, showcasing its significant impact in the mental health sector.
See More
Robert Bessler Sells LifeStance Shares Worth $492K
- Transaction Overview: Director Robert Bessler sold 69,899 shares of LifeStance Health Group in multiple open-market transactions on April 23 and 24, valued at approximately $492,000, indicating his ongoing engagement with the company's stock.
- Holding Changes: This sale represented 2.47% of Bessler's total holdings, leaving him with 57,619 shares directly and over 2.7 million shares indirectly, demonstrating his substantial economic interest in the company.
- Company Performance: LifeStance reported $1.4 billion in revenue for 2025, a 14% year-over-year increase, and achieved a net income of $9.7 million, marking a significant turnaround from a net loss of $57.4 million in 2024, showcasing strong business performance and growth potential.
- Market Reaction: Despite Bessler's stock sale, LifeStance shares recently hit a 52-week high of $8.09, with projected revenue of $1.6 billion for 2026, reflecting strong market confidence in the company's future growth prospects.
See More
Director Robert Bessler Sells Shares of LifeStance Health Group
- Share Sale Details: Director Robert Bessler sold 69,899 shares of LifeStance Health Group between April 23 and 24, 2026, for approximately $492,000, representing 2.47% of his total holdings, indicating his continued confidence in the company despite the sale.
- Ownership Structure: Post-transaction, Bessler retains about 57,619 shares directly and 2.7 million shares indirectly, demonstrating a strong commitment to LifeStance as a long-term investment even after partial divestment.
- Company Performance: LifeStance reported a 14% year-over-year revenue increase in 2025, reaching $1.4 billion, and successfully reversed a net loss from 2024 into a net income of $9.7 million, showcasing a robust business recovery.
- Market Outlook: Although LifeStance's forward price-to-sales ratio has risen to 2, reflecting its stock price increase, the company expects revenue to reach $1.6 billion in 2026, indicating ongoing growth potential, prompting investors to carefully assess its investment value.
See More
S&P Dow Jones Indices: LifeStance Health Group to Take the Place of Golden Entertainment in S&P SmallCap 600 Starting May 1 Before Market Opens
Company Announcement: S&P Dow Jones Indices has announced that Lifestance Health Group will replace Golden Entertainment in the S&P SmallCap 600 index.
Effective Date: This change will take effect prior to the opening of trading on May 1.
See More
Lifestance Health Group to be Added to S&P SmallCap 600, According to S&P Dow Jones Indices
- S&P Dow Jones Indices Update: The S&P Dow Jones Indices has announced that Lifestance Health Group will be joining the S&P SmallCap 600 index.
- Impact on Market: This inclusion is expected to enhance the visibility and credibility of Lifestance Health Group within the financial markets.
See More
Wall Street's Optimistic Price Targets for Stocks
- LifeStance Health Risks: LifeStance Health Group (LFST) has a revenue base of only $1.42 billion, lacking the economies of scale enjoyed by industry giants, and its free cash flow margin of 0.5% over the past five years constrains its ability to self-fund growth or return capital, with a current share price of $6.90 reflecting a forward P/E of 22.9.
- Meta's Growth Potential: Meta (META) has achieved a 29.9% annual growth in average revenue per user over the past two years, and its stock buybacks have led to a 51.3% increase in earnings per share, with a current share price of $672.76 and a forward EV/EBITDA of 12.2, indicating strong profitability and investment returns.
- Permian Resources' Strong Performance: Permian Resources (PR) has seen an impressive annual revenue growth of 43.3% over the last decade, boasting a best-in-class gross margin of 75.7% and a free cash flow margin of 27.2%, with a current stock price of $20.40 reflecting a forward P/E of 10.4, showcasing flexibility in capital deployment.
- Market Outlook Analysis: While analysts set optimistic price targets for these stocks, caution is advised as market sentiment can lead to overly optimistic forecasts, prompting investors to focus on the companies' fundamentals and potential risks.
See More
LifeStance Health Group to Release Q1 2026 Earnings
- Earnings Release Schedule: LifeStance Health Group is set to release its Q1 2026 earnings before the market opens on May 7, 2026, reflecting the company's ongoing commitment to transparency and investor communication.
- Conference Call Details: The company will host an earnings conference call at 8:30 a.m. Eastern Time on the same day, with investors able to dial in at 1-800-715-9871, demonstrating the importance placed on investor engagement.
- Webcast Availability: The earnings call will be accessible via a real-time audio webcast on the LifeStance Investor Relations website, with related materials posted prior to the call, enhancing the accessibility of information for stakeholders.
- Company Background: Founded in 2017, LifeStance has become one of the largest outpatient mental health care providers in the U.S., employing approximately 8,000 professionals across 33 states and over 550 centers, showcasing its significant impact in the mental health sector.
See More
